The Human Variable 

Personalized CRISPR Remission™ for Long COVID introduces a state-dependent gene editing framework based on biological readiness, stabilization, and recovery to improve timing, safety, and durability in immune-volatile disease.

Pediatric Long COVID in the U.S. may affect 6–10 million children. This analysis explores prevalence, symptoms, underdiagnosis, and public health implications using US-CCUC modeling.

CDF-Peds-LC™ was developed as CYNAERA’s proposed Composite Diagnostic Fingerprint for Pediatric Long COVID. It is a structured recognition and tracking framework designed to identify probable pediatric Long COVID through five interlocking domains: post-infection onset, multisystem symptom burden, post-exertional patterning, functional disruption, and fluctuation or relapse over time.

For many people living with ME/CFS, myself included, mold exposures contribute to flare instability, worsening fatigue, cognitive dysfunction, headaches, autonomic disruption, and reduced functional capacity. What appears to be a sudden symptom crash may, in many cases, reflect the interaction between chronic illness and a destabilizing indoor environment.

AI-driven environmental amplification interacts with a large and growing population of individuals with infection-associated chronic conditions (e.g., Long COVID, ME/CFS), who exhibit heightened physiological sensitivity to environmental triggers such as fine particulate matter (PM₂.₅), heat stress, and atmospheric instability. If you want an alternate tone that leans slightly more policy-facing:

Climate accelerated wildfires, burning over 7.7 million acres in 2020–2021, threaten the 65–75 million Americans with Infection-Associated Chronic Conditions (IACCs), including Long COVID, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Postural Orthostatic Tachycardia Syndrome (POTS), Mast Cell Activation Syndrome (MCAS), and Small Fiber Neuropathy (SFN) If you want an alternate tone that leans slightly more policy-facing: